One-third of patients with PSA levels below 0.2 ng/mL after radical prostatectomy have recurrent disease identifiable by PSMA PET. More than one-third of patients with PSA levels less than 0.5 ng/mL ...

Those results also were reported in The New England Journal of Medicine. PSMA-PET scans of Michael Rosenblum before treatment (left) show prostate cancer metastases (small dark spots) throughout his ...

"It’s crucial that patients and their families know about this new option," said Dr. William Russell, an oncology radiologist ...

New research highlights the significance of timing and tumour location when evaluating PSMA PET scans following radiotherapy ...

Gozellix, a PSMA-PET imaging agent, is FDA-approved for detecting prostate cancer metastasis and recurrence, enhancing access to advanced imaging. The approval is supported by data from the PSMA-PreRP ...

Gallium Ga 68 gozetotide is composed of a human PSMA-targeting ligand peptide conjugated to the radioisotope Ga 68, a β+ emitting radionuclide that allows for PET imaging. It works by binding to ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET[1] imaging agent Illuccix® ...

Guidelines created by a multi-disciplinary panel of specialists focus on implementation of novel treatments and technologies for which level 1 evidence is lacking.

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) ...

Malaysia, meanwhile, is emerging as a prominent leader in adopting advanced prostate cancer treatments and diagnostics, ...